Piromelatine, formerly known as NEU-P11, is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Pre-clinical studies showed antinociceptive, antihypertensive and cognitive benefits in rat disease models of pain, hypertension, and Alzheimer's disease. References: Zisapel N. Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11. doi: 10.1517/13543784.2015.987340. Epub 2014 Nov 25. Review. PubMed PMID: 25423562.

纯度：≥98%

CAS：946846-83-9